within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CA01_Gonadorelin;

model Gonadorelin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.5277777777777775e-06,
    adminDuration = 600,
    adminMass = 0.1 / 1000000,
    adminCount = 1,
    Vd = 0.013699999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0065,
    k12 = 4.9166666666666665e-06,
    k21 = 4.9166666666666665e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gonadorelin</td></tr><tr><td>ATC code:</td><td>H01CA01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gonadorelin is a synthetic decapeptide identical to the hypothalamic gonadotropin-releasing hormone (GnRH). It is primarily used for diagnostic purposes to evaluate pituitary function or to induce ovulation in assisted reproduction. It is approved in certain countries but is largely replaced by newer GnRH analogues for clinical applications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers following intravenous bolus administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H01CA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Gonadorelin;
